EASIX for prediction of survival in lower-risk myelodysplastic syndromes
| Autor: | Guido Kobbe, Thomas Luft, Maximilian Merz, Jennifer Kaivers, Manuela Hummel, Axel Benner, Almuth Maria Anni Merz, Anna Jauch, Ulrich Germing, Peter Dreger, Aleksandar Radujkovic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Lower risk lcsh:RC254-282 Models Biological Article Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Sex Factors Predictive Value of Tests Internal medicine medicine Humans Transplantation Homologous Survival rate Aged Proportional Hazards Models Retrospective Studies Aged 80 and over Proportional hazards model business.industry Myelodysplastic syndromes Hazard ratio Age Factors Hematopoietic Stem Cell Transplantation Retrospective cohort study Hematology Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Transplantation Survival Rate Leukemia Myeloid Acute 030104 developmental biology Risk factors 030220 oncology & carcinogenesis Myelodysplastic Syndromes Cohort Female business Myelodysplastic syndrome Follow-Up Studies |
| Zdroj: | Blood Cancer Journal Blood Cancer Journal, Vol 9, Iss 11, Pp 1-7 (2019) |
| ISSN: | 2044-5385 |
| Popis: | Patients with myelodysplastic syndromes (MDS) are at risk of early death from cardiovascular complications due to the link between clonal hematopoiesis and endothelial dysfunction. EASIX (Endothelial Activation and Stress Index) has been established to predict endothelial complications after allogeneic transplantation. We investigated the impact of EASIX measured at first diagnosis on survival of patients with lower- and higher-risk MDS (no allogeneic transplantation) in two independent institutions: n = 192 (training cohort) and n = 333 (validation cohort). Serum markers of endothelial cell distress were measured and correlated to EASIX. While no effects of EASIX on survival were observed in higher-risk patients, EASIX was associated with shorter survival in patients with lower-risk MDS in both cohorts (univariate: Cohort I: hazard ratio (HR): 1.46; 95% confidence interval (CI) 1.24–1.71; p-value p-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|